All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

bleomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	4742	11056-06-7

Description:

Molecule	Description
Synonyms: bleomycin bleomycins bleomycin sulfate bleomycin hydrochloride bleomycin HCl	A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Molecular weight: 2841.07 Formula: C110H168N37O42S5 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 688.97 ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.43 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.26 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.90 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	20 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
July 31, 1973	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	322.50	27.01	191	7386	118258	63363187
Hepatitis B reactivation	215.02	27.01	54	7523	3083	63478362
Neutropenia	210.93	27.01	171	7406	174834	63306611
Pulmonary toxicity	183.76	27.01	61	7516	9394	63472051
Ovarian germ cell teratoma	148.93	27.01	22	7555	56	63481389
Acute hepatic failure	131.23	27.01	57	7520	18270	63463175
Teratoma	126.64	27.01	21	7556	135	63481310
Second primary malignancy	125.87	27.01	44	7533	7909	63473536
Mucosal inflammation	90.47	27.01	61	7516	46867	63434578
Acute myeloid leukaemia	90.10	27.01	43	7534	17104	63464341
Deafness	85.22	27.01	42	7535	17915	63463530
Teratoma benign	82.02	27.01	13	7564	60	63481385
Myelodysplastic syndrome	81.94	27.01	40	7537	16714	63464731
Pancytopenia	78.91	27.01	76	7501	96857	63384588
Bone marrow failure	71.04	27.01	44	7533	29246	63452199
Interstitial lung disease	64.97	27.01	56	7521	61852	63419593
Respiratory failure	64.92	27.01	70	7507	101788	63379657
Cutaneous calcification	61.57	27.01	11	7566	115	63481330
Chloroma	60.34	27.01	12	7565	231	63481214
Febrile bone marrow aplasia	59.75	27.01	25	7552	7300	63474145
Tissue infiltration	59.29	27.01	14	7563	615	63480830
Disease progression	59.11	27.01	73	7504	122685	63358760
Pulmonary fibrosis	58.79	27.01	44	7533	39765	63441680
Basal ganglion degeneration	58.48	27.01	13	7564	435	63481010
Product use in unapproved indication	58.21	27.01	88	7489	178992	63302453
Synovial sarcoma	55.24	27.01	9	7568	51	63481394
Premature baby	55.02	27.01	33	7544	20702	63460743
Respiratory symptom	54.80	27.01	19	7558	3328	63478117
Necrotising gastritis	53.11	27.01	9	7568	67	63481378
Acute respiratory distress syndrome	51.18	27.01	33	7544	23501	63457944
Premature menopause	49.67	27.01	13	7564	873	63480572
Uterine enlargement	49.55	27.01	14	7563	1254	63480191
Drug resistance	49.48	27.01	32	7545	22901	63458544
Thrombocytopenia	44.50	27.01	71	7506	151086	63330359
Foetal exposure during pregnancy	44.25	27.01	34	7543	31928	63449517
Anaemia	43.45	27.01	103	7474	293327	63188118
Inguinal hernia	43.21	27.01	14	7563	1993	63479452
Aplasia	43.20	27.01	17	7560	4242	63477203
Peripheral sensory neuropathy	43.18	27.01	20	7557	7431	63474014
Combined immunodeficiency	42.96	27.01	8	7569	107	63481338
Off label use	42.79	27.01	176	7401	674286	62807159
Anaesthesia	42.67	27.01	10	7567	425	63481020
Primary immunodeficiency syndrome	42.48	27.01	7	7570	43	63481402
Hyperpyrexia	42.19	27.01	16	7561	3616	63477829
Malignant neoplasm progression	41.39	27.01	50	7527	82071	63399374
Psychogenic seizure	41.36	27.01	13	7564	1679	63479766
Sarcoidosis	40.91	27.01	19	7558	7103	63474342
Exposure during pregnancy	40.32	27.01	69	7508	155478	63325967
Lung disorder	40.01	27.01	43	7534	62218	63419227
Leukaemia	39.90	27.01	16	7561	4192	63477253
Flagellate dermatitis	39.34	27.01	8	7569	173	63481272
Cardiotoxicity	37.84	27.01	19	7558	8419	63473026
Pleuroparenchymal fibroelastosis	36.60	27.01	7	7570	109	63481336
Vulvovaginal inflammation	36.15	27.01	10	7567	829	63480616
Pain	36.09	27.01	22	7555	740606	62740839
Septic shock	35.93	27.01	42	7535	66587	63414858
Lymphopenia	35.71	27.01	24	7553	18303	63463142
Neurological decompensation	35.69	27.01	13	7564	2625	63478820
Hypochromic anaemia	35.60	27.01	12	7565	1930	63479515
Dysaesthesia	35.57	27.01	15	7562	4463	63476982
Myelosuppression	34.54	27.01	26	7551	23677	63457768
Rash	34.51	27.01	12	7565	560859	62920586
Traumatic lung injury	33.86	27.01	11	7566	1578	63479867
Tumour lysis syndrome	33.85	27.01	18	7559	8972	63472473
Transdifferentiation of neoplasm	33.77	27.01	5	7572	13	63481432
Haemophagocytic lymphohistiocytosis	33.72	27.01	19	7558	10608	63470837
Monoplegia	33.25	27.01	13	7564	3188	63478257
Haematotoxicity	33.14	27.01	18	7559	9358	63472087
Encephalitis viral	32.93	27.01	11	7566	1721	63479724
Acute promyelocytic leukaemia	30.71	27.01	9	7568	918	63480527
Capillary leak syndrome	30.36	27.01	11	7566	2189	63479256
Pneumocystis jirovecii pneumonia	30.23	27.01	21	7556	16893	63464552
Abdominal compartment syndrome	29.90	27.01	8	7569	585	63480860
Cytopenia	29.57	27.01	18	7559	11583	63469862
Meningitis streptococcal	28.64	27.01	6	7571	151	63481294

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	404.70	22.06	322	9507	136527	34810575
Second primary malignancy	349.90	22.06	117	9712	7769	34939333
Acute myeloid leukaemia	257.62	22.06	118	9711	18152	34928950
Pulmonary toxicity	252.11	22.06	86	9743	6061	34941041
Azoospermia	162.69	22.06	35	9794	406	34946696
Pneumonitis	131.09	22.06	94	9735	33784	34913318
Pulmonary fibrosis	125.65	22.06	73	9756	18323	34928779
Interstitial lung disease	118.57	22.06	117	9712	65165	34881937
Myelodysplastic syndrome	117.53	22.06	71	9758	19137	34927965
Neutropenia	111.24	22.06	175	9654	156603	34790499
Acute respiratory distress syndrome	104.91	22.06	74	9755	25895	34921207
Bone marrow failure	75.69	22.06	64	9765	29189	34917913
Flagellate dermatitis	75.42	22.06	14	9815	70	34947032
Cardiotoxicity	74.89	22.06	35	9794	5613	34941489
Endocarditis noninfective	74.20	22.06	15	9814	125	34946977
Traumatic lung injury	69.21	22.06	22	9807	1238	34945864
Pneumomediastinum	62.74	22.06	24	9805	2343	34944759
Pneumocystis jirovecii pneumonia	61.26	22.06	48	9781	19662	34927440
Papillary thyroid cancer	59.77	22.06	17	9812	652	34946450
Chronic myeloid leukaemia	56.98	22.06	22	9807	2202	34944900
Respiratory failure	55.52	22.06	105	9724	108467	34838635
Pyrexia	53.13	22.06	209	9620	332804	34614298
Cytomegalovirus chorioretinitis	53.09	22.06	24	9805	3565	34943537
Vena cava thrombosis	49.68	22.06	17	9812	1205	34945897
Scleroderma	49.18	22.06	18	9811	1554	34945548
Testicular disorder	48.03	22.06	15	9814	796	34946306
Thrombocytopenia	47.89	22.06	123	9706	156124	34790978
Myositis	47.79	22.06	34	9795	12036	34935066
Pneumothorax	47.79	22.06	41	9788	19051	34928051
Coronary artery thrombosis	47.05	22.06	19	9810	2140	34944962
Lung disorder	46.55	22.06	53	9776	34643	34912459
Leukopenia	44.16	22.06	70	9759	62786	34884316
Off label use	43.56	22.06	232	9597	419292	34527810
Osteonecrosis	43.56	22.06	35	9794	14855	34932247
Malignant neoplasm progression	42.34	22.06	83	9746	87963	34859139
Pulmonary embolism	41.23	22.06	83	9746	89663	34857439
Chloroma	40.91	22.06	12	9817	514	34946588
Teratoma	40.54	22.06	7	9822	21	34947081
Mucosal inflammation	38.83	22.06	51	9778	38571	34908531
Subcutaneous emphysema	38.57	22.06	14	9815	1180	34945922
Autoimmune neutropenia	38.49	22.06	10	9819	271	34946831
Deafness	38.42	22.06	29	9800	11236	34935866
Haematotoxicity	36.94	22.06	25	9804	8169	34938933
Pancytopenia	36.75	22.06	82	9747	95075	34852027
Carotid artery thrombosis	36.18	22.06	10	9819	345	34946757
Blood pressure decreased	35.67	22.06	57	9772	51458	34895644
Taeniasis	35.33	22.06	7	9822	52	34947050
Vascular access site occlusion	35.22	22.06	7	9822	53	34947049
Product use in unapproved indication	34.41	22.06	91	9738	117408	34829694
Acute myocardial infarction	33.89	22.06	57	9772	53662	34893440
Vocal cord inflammation	33.57	22.06	7	9822	69	34947033
Premature ageing	32.62	22.06	7	9822	80	34947022
Cerebral infarction	31.94	22.06	39	9790	27416	34919686
Arterial thrombosis	31.87	22.06	13	9816	1502	34945600
Fall	31.54	22.06	9	9820	202876	34744226
Neutropenic sepsis	31.30	22.06	28	9801	13739	34933363
Ichthyosis	30.92	22.06	7	9822	104	34946998
Lung infiltration	30.85	22.06	27	9802	12878	34934224
Embolism arterial	30.10	22.06	10	9819	647	34946455
Testicular malignant teratoma	30.07	22.06	5	9824	11	34947091
Disease progression	29.92	22.06	82	9747	107995	34839107
Pneumonia salmonella	29.78	22.06	6	9823	49	34947053
Cardiac dysfunction	29.49	22.06	14	9815	2324	34944778
Peripheral artery thrombosis	29.36	22.06	14	9815	2346	34944756
Therapy partial responder	28.96	22.06	23	9806	9593	34937509
Septic shock	28.96	22.06	63	9766	71771	34875331
Osteosarcoma	28.69	22.06	8	9821	285	34946817
Neoplasm progression	28.58	22.06	34	9795	23266	34923836
Dizziness	28.37	22.06	13	9816	218508	34728594
Asthenospermia	28.34	22.06	6	9823	64	34947038
Splenic infarction	27.94	22.06	13	9816	2062	34945040
Febrile bone marrow aplasia	27.70	22.06	21	9808	8188	34938914
Pain	26.84	22.06	12	9817	204663	34742439
Organising pneumonia	26.37	22.06	18	9811	5961	34941141
Rash	26.31	22.06	15	9814	222737	34724365
Death	26.15	22.06	45	9784	398004	34549098
Paternal exposure timing unspecified	25.62	22.06	5	9824	34	34947068
Trisomy 13	25.05	22.06	4	9825	6	34947096
Cerebral venous thrombosis	24.95	22.06	9	9820	745	34946357
Spindle cell sarcoma	24.42	22.06	6	9823	129	34946973
Acute promyelocytic leukaemia	24.40	22.06	8	9821	497	34946605
Fatigue	24.25	22.06	42	9787	370611	34576491
Drug ineffective	24.08	22.06	214	9615	456537	34490565
Sarcoidosis	23.87	22.06	13	9816	2875	34944227
Ischaemic cerebral infarction	23.86	22.06	10	9819	1237	34945865
Arthralgia	23.86	22.06	9	9820	170032	34777070
Guillain-Barre syndrome	23.75	22.06	17	9812	6070	34941032
Blindness	23.75	22.06	25	9804	14961	34932141
Product dose omission issue	23.46	22.06	3	9826	119708	34827394
Respiratory disorder	23.44	22.06	28	9801	19236	34927866
Diaphragm muscle weakness	23.26	22.06	6	9823	158	34946944
Renal salt-wasting syndrome	23.05	22.06	7	9822	338	34946764
Cerebral artery stenosis	22.87	22.06	7	9822	347	34946755
Heart disease congenital	22.82	22.06	10	9819	1380	34945722
Vocal cord paralysis	22.78	22.06	9	9820	957	34946145
Subdural haemorrhage	22.66	22.06	13	9816	3178	34943924
Testicular cancer metastatic	22.17	22.06	5	9824	73	34947029

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	713.92	19.69	485	15241	230514	79498148
Second primary malignancy	449.08	19.69	150	15576	14200	79714462
Pulmonary toxicity	368.62	19.69	126	15600	12788	79715874
Acute myeloid leukaemia	359.99	19.69	157	15569	30728	79697934
Neutropenia	292.52	19.69	320	15406	287390	79441272
Myelodysplastic syndrome	205.13	19.69	106	15620	30195	79698467
Interstitial lung disease	184.77	19.69	163	15563	112437	79616225
Pulmonary fibrosis	160.55	19.69	103	15623	44009	79684653
Acute respiratory distress syndrome	155.71	19.69	101	15625	43966	79684696
Pneumonitis	150.47	19.69	112	15614	60748	79667914
Teratoma	147.36	19.69	26	15700	142	79728520
Ovarian germ cell teratoma	137.87	19.69	22	15704	56	79728606
Bone marrow failure	128.44	19.69	95	15631	51012	79677650
Pancytopenia	119.42	19.69	155	15571	165590	79563072
Pneumocystis jirovecii pneumonia	113.57	19.69	74	15652	32434	79696228
Respiratory failure	113.28	19.69	158	15568	180753	79547909
Thrombocytopenia	110.59	19.69	192	15534	265067	79463595
Flagellate dermatitis	110.35	19.69	22	15704	251	79728411
Mucosal inflammation	105.49	19.69	100	15626	75480	79653182
Malignant neoplasm progression	102.36	19.69	130	15596	135860	79592802
Teratoma benign	101.52	19.69	17	15709	64	79728598
Peripheral sensory neuropathy	89.33	19.69	46	15680	12987	79715675
Chloroma	87.64	19.69	22	15704	748	79727914
Traumatic lung injury	86.85	19.69	28	15698	2363	79726299
Haematotoxicity	84.51	19.69	47	15679	15472	79713190
Pneumomediastinum	82.51	19.69	30	15696	3637	79725025
Lung disorder	82.15	19.69	90	15636	80467	79648195
Chronic myeloid leukaemia	78.82	19.69	29	15697	3635	79725027
Disease progression	77.46	19.69	134	15592	184228	79544434
Cardiotoxicity	74.77	19.69	40	15686	12199	79716463
Product use in unapproved indication	74.37	19.69	157	15569	250202	79478460
Endocarditis noninfective	72.01	19.69	15	15711	216	79728446
Pyrexia	69.64	19.69	291	15435	678418	79050244
Pain	64.77	19.69	29	15697	703773	79024889
Pneumothorax	63.06	19.69	49	15677	28274	79700388
Sarcoidosis	61.72	19.69	31	15695	8304	79720358
Off label use	59.36	19.69	342	15384	906873	78821789
Febrile bone marrow aplasia	59.03	19.69	35	15691	12985	79715677
Myelitis	55.43	19.69	20	15706	2371	79726291
Cutaneous calcification	54.59	19.69	11	15715	133	79728529
Rash	54.49	19.69	23	15703	578335	79150327
Therapy partial responder	54.46	19.69	37	15689	17360	79711302
Necrotising gastritis	54.05	19.69	10	15716	74	79728588
Pleuroparenchymal fibroelastosis	53.78	19.69	11	15715	144	79728518
Acute promyelocytic leukaemia	52.28	19.69	17	15709	1474	79727188
Leukopenia	50.61	19.69	86	15640	116427	79612235
Subcutaneous emphysema	49.19	19.69	17	15709	1777	79726885
Osteonecrosis	48.89	19.69	44	15682	31051	79697611
Septic shock	48.60	19.69	87	15639	122714	79605948
Azoospermia	47.32	19.69	10	15716	155	79728507
Synovial sarcoma	46.98	19.69	9	15717	82	79728580
Stem cell transplant	46.94	19.69	20	15706	3684	79724978
Coronary artery thrombosis	46.88	19.69	19	15707	3087	79725575
Papillary thyroid cancer	46.67	19.69	18	15708	2568	79726094
Deafness	45.97	19.69	36	15690	21001	79707661
Myositis	44.49	19.69	34	15692	19134	79709528
Cytomegalovirus chorioretinitis	42.36	19.69	21	15705	5469	79723193
Basal ganglion degeneration	42.16	19.69	11	15715	437	79728225
Tissue infiltration	41.88	19.69	12	15714	679	79727983
Cytopenia	40.52	19.69	33	15693	20350	79708312
Tumour lysis syndrome	39.87	19.69	35	15691	23904	79704758
Joint swelling	39.85	19.69	5	15721	288641	79440021
Myelosuppression	39.29	19.69	44	15682	40252	79688410
Combined immunodeficiency	39.16	19.69	8	15718	104	79728558
Peripheral swelling	38.90	19.69	4	15722	269613	79459049
Uterine enlargement	38.64	19.69	12	15714	896	79727766
Haemophagocytic lymphohistiocytosis	38.53	19.69	33	15693	21804	79706858
Acute lymphocytic leukaemia	38.32	19.69	19	15707	4950	79723712
Weight increased	37.82	19.69	5	15721	277381	79451281
Taeniasis	37.81	19.69	7	15719	52	79728610
Product dose omission issue	37.51	19.69	3	15723	247534	79481128
Anaemia	37.34	19.69	180	15546	444835	79283827
Scleroderma	36.46	19.69	19	15707	5491	79723171
Tooth malformation	36.42	19.69	8	15718	150	79728512
Fall	36.31	19.69	26	15700	487603	79241059
Primary immunodeficiency syndrome	36.04	19.69	7	15719	69	79728593
Vulvovaginal inflammation	35.42	19.69	10	15716	536	79728126
Lung infiltration	35.19	19.69	32	15694	22880	79705782
Vascular access site occlusion	35.18	19.69	7	15719	79	79728583
Leukaemia	35.17	19.69	19	15707	5906	79722756
Diarrhoea	35.15	19.69	76	15650	880413	78848249
Cerebral infarction	34.84	19.69	44	15682	45632	79683030
Premature ageing	34.63	19.69	7	15719	86	79728576
Vena cava thrombosis	34.61	19.69	15	15711	2880	79725782
Autoimmune neutropenia	34.47	19.69	10	15716	591	79728071
Pulmonary embolism	33.94	19.69	92	15634	171562	79557100
Acute myocardial infarction	33.62	19.69	57	15669	76979	79651683
Aplasia	32.80	19.69	20	15706	7800	79720862
Asthenospermia	32.60	19.69	6	15720	43	79728619
Arthralgia	32.53	19.69	39	15687	571764	79156898
Cerebral venous thrombosis	32.05	19.69	14	15712	2739	79725923
Hepatitis B reactivation	31.89	19.69	18	15708	6090	79722572
Testicular malignant teratoma	31.85	19.69	5	15721	11	79728651
Organising pneumonia	31.26	19.69	22	15704	10917	79717745
Anaesthesia	31.26	19.69	9	15717	518	79728144
Pneumonia salmonella	30.91	19.69	6	15720	59	79728603
Ichthyosis	30.72	19.69	7	15719	156	79728506
Anxiety	30.47	19.69	6	15720	248506	79480156
Psychogenic seizure	29.79	19.69	12	15714	1919	79726743
Hodgkin's disease recurrent	29.42	19.69	5	15721	21	79728641
Swelling	29.31	19.69	4	15722	216707	79511955
Hyperpyrexia	29.26	19.69	17	15709	6075	79722587
Respiratory disorder	29.23	19.69	40	15686	44816	79683846
Arterial thrombosis	29.20	19.69	13	15713	2661	79726001
Neoplasm progression	29.13	19.69	43	15683	51639	79677023
Brain oedema	28.86	19.69	30	15696	25233	79703429
Abdominal discomfort	28.82	19.69	7	15719	250720	79477942
Bacterial infection	28.53	19.69	33	15693	31247	79697415
Sinusitis	27.93	19.69	3	15723	195498	79533164
Guillain-Barre syndrome	27.90	19.69	19	15707	8946	79719716
Dizziness	27.76	19.69	38	15688	526403	79202259
Peripheral sensorimotor neuropathy	27.72	19.69	13	15713	2997	79725665
Lymphopenia	27.48	19.69	32	15694	30525	79698137
Nasopharyngitis	27.45	19.69	8	15718	253873	79474789
Vocal cord inflammation	27.42	19.69	7	15719	255	79728407
Blood pressure decreased	26.75	19.69	60	15666	99406	79629256
Ototoxicity	26.68	19.69	13	15713	3261	79725401
Encephalitis viral	26.45	19.69	12	15714	2567	79726095
Blood pressure increased	26.12	19.69	5	15721	211355	79517307
Left ventricular dysfunction	25.81	19.69	25	15701	19336	79709326
Embolism arterial	25.39	19.69	10	15716	1508	79727154
Splenic infarction	25.30	19.69	13	15713	3651	79725011
Death	25.04	19.69	46	15680	566468	79162194
Infusion site joint movement impairment	24.58	19.69	4	15722	12	79728650
Renal salt-wasting syndrome	24.44	19.69	8	15718	708	79727954
Testicular cancer metastatic	24.41	19.69	5	15721	66	79728596
Diaphragm muscle weakness	24.40	19.69	6	15720	187	79728475
Monoplegia	24.31	19.69	13	15713	3958	79724704
Fatigue	24.19	19.69	98	15628	929629	78799033
B precursor type acute leukaemia	24.01	19.69	7	15719	421	79728241
Pruritus	23.41	19.69	26	15700	394622	79334040
Congestive cardiomyopathy	23.26	19.69	19	15707	11761	79716901
Spindle cell sarcoma	23.25	19.69	6	15720	228	79728434
Lung diffusion test decreased	23.22	19.69	9	15717	1301	79727361
Peripheral artery thrombosis	23.02	19.69	12	15714	3471	79725191
Neurotoxicity	22.72	19.69	30	15696	32488	79696174
Lymphadenopathy	22.70	19.69	39	15687	53208	79675454
Urinary tract infection	22.64	19.69	13	15713	274499	79454163
Insomnia	22.64	19.69	10	15716	245160	79483502
Oropharyngeal squamous cell carcinoma	22.49	19.69	6	15720	260	79728402
Transdifferentiation of neoplasm	22.32	19.69	5	15721	103	79728559
Hodgkin's disease nodular sclerosis	22.21	19.69	4	15722	25	79728637
Dysaesthesia	22.11	19.69	14	15712	5834	79722828
Subdural haemorrhage	21.89	19.69	14	15712	5934	79722728
Infusion related reaction	21.88	19.69	9	15717	230228	79498434
Muscle spasms	21.87	19.69	4	15722	174726	79553936
Hypothyroidism	21.85	19.69	38	15688	52354	79676308
Carotid artery thrombosis	21.56	19.69	11	15715	3042	79725620
Abdominal compartment syndrome	21.49	19.69	9	15717	1588	79727074
Neuropathy peripheral	21.48	19.69	69	15657	141236	79587426
Infusion site ulcer	21.46	19.69	4	15722	31	79728631
Overdose	21.44	19.69	5	15721	184201	79544461
Venoocclusive liver disease	21.20	19.69	18	15708	11753	79716909
Deep vein thrombosis	21.14	19.69	62	15664	120857	79607805
Infusion site hypoaesthesia	20.92	19.69	4	15722	36	79728626
Invasive lobular breast carcinoma	20.52	19.69	7	15719	704	79727958
Ischaemic cerebral infarction	20.46	19.69	10	15716	2525	79726137
Klebsiella infection	20.40	19.69	20	15706	15700	79712962
Osteosarcoma	20.25	19.69	6	15720	382	79728280
Cerebral artery stenosis	20.01	19.69	7	15719	758	79727904
Musculoskeletal stiffness	19.88	19.69	5	15721	175003	79553659
Chills	19.78	19.69	73	15653	160161	79568501
Hypochromic anaemia	19.69	19.69	10	15716	2741	79725921

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Other cytotoxic antibiotics
CHEBI has role	CHEBI:25212	metabolites
CHEBI has role	CHEBI:35610	antineoplastic agents
MeSH PA	D000903	Antibiotics, Antineoplastic
MeSH PA	D000970	Antineoplastic Agents
FDA EPC	N0000180854	Cytoprotective Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diffuse non-Hodgkin's lymphoma, large cell	indication	109969005
Hodgkin's disease	indication	118599009
Non-Hodgkin's lymphoma	indication	118601006
Malignant tumor of head and/or neck	indication	255056009
Follicular non-Hodgkin's lymphoma	indication	308121000
Malignant tumor of cervix	indication	363354003	DOID:4362
Malignant tumor of penis	indication	363516004	DOID:11615
International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma	indication	385370007
Squamous cell carcinoma	indication	402815007	DOID:1749
Pleural Malignant Effusions	indication
Testicular Germ Cell Tumor	indication
Mycosis fungoides	off-label use	118618005
Ovarian Germ Cell Tumor Carcinoma	off-label use

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Aspartyl/asparaginyl beta-hydroxylase	Enzyme	Q12797	ASPH_HUMAN		IC50	5.83		CHEMBL

External reference:

ID	Source
D02177	KEGG_DRUG
4019637	VUID
N0000147730	NUI
9041-93-4	SECONDARY_CAS_RN
4018135	VANDF
4019637	VANDF
CHEBI:3139	CHEBI
CHEMBL403664	ChEMBL_ID
2721	INN_ID
67763-87-5	SECONDARY_CAS_RN
DB00290	DRUGBANK_ID
40S1VHN69B	UNII
1621	RXNORM
4293	MMSL
9784	MMSL
d00177	MMSL
002661	NDDF
004820	NDDF
009872	NDDF
15660006	SNOMEDCT_US
372843005	SNOMEDCT_US
703085003	SNOMEDCT_US
76591000	SNOMEDCT_US
C0005740	UMLSCUI
D001761	MESH_DESCRIPTOR_UI
CHEMBL3085504	ChEMBL_ID
5360373	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9240	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9240	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9241	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9241	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3154	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	19 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3155	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	19 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-886	POWDER, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-908	POWDER, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-136	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	12 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-137	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	12 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	69097-364	INJECTION	15 [USPU]	INTRAMUSCULAR	ANDA	20 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1567	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15000 [iU]	INTRA-ARTERIAL	UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE	18 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1567	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15000 [iU]	INTRA-ARTERIAL	UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE	18 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	71288-106	POWDER, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	24 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	71288-107	POWDER, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	24 sections